Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"enzalutamide"”.
-
Antioxidant Programs Are Essential for Enzalutamide-Resistant Prostate Cancer
… androgen receptor (AR) antagonists, such as enzalutamide, is common in patients with advanced prostate cancer (PCa). In order to identify which patients will develop therapy resistance and the underlying cause, it is critical to characterize detailed mechanisms of resistance to improve …
-
Investigation of the role of Col4a1 and Itga11 in enzalutamide resistance of prostate cancer cells
… in the development of resistance to antiandrogen Enzalutamide in murine prostate cancer bone metastasis cell line Myc-CaP Bo 6943, which is susceptible to treatment. It also aimed to determine the potential effect of tumour cell-derived matrix (CDM) on macrophage polarization. Myc-Cap Bo 6943 cell …
-
Role of the extracellular matrix-integrin interaction in enzalutamide resistance of bone metastatic castration-resistant prostate cancer
… to androgen-deprivation therapy (ADT). Enzalutamide (Enz) is a second-generation androgen-receptor (AR) antagonist, developed to treat bone mCRPC by blocking the androgen signalling pathway. However, the emergence of resistance to Enz significantly limits therapeutic options for bone …
-
Characterizing glucocorticoid receptor in metastatic castration resistant prostate cancer
… (GR) signaling and relevance in the context of enzalutamide resistant prostate cancer cells. Enzalutamide is a drug that functions to dampen androgen receptor (AR) signaling, thus inhibiting cancer dependency on the receptor protein. Although the application of the drug reduces AR signaling in …
-
Targeting anti-androgen resistance in prostate cancer using preclinical models with physiological nutrient levels
… While anti-androgen therapies such as Enzalutamide can be effective against prostate cancer, 60% of patients will develop Enzalutamide resistance which is currently incurable. Since AR signalling regulates metabolism, a hallmark of cancer, we set out to characterise metabolic …
-
Hormonal modulation of disseminating endodontic infections
… of estrogen and the androgen receptor antagonist enzalutamide (ENZ) on DEI will be evaluated in adult male group through direct observation of facial abscess formation, fatigue, and malaise. Additionally, survival rates, weight change, and spleen weights will be recorded and compared between …
-
Targeting DNA Repair in Prostate Cancer: Therapeutic Combinations & Disease Models
… interactions between the AR signalling inhibitor Enzalutamide (Enza) when combined with either PARP inhibitor Olaparib or ATM inhibition (ATMi). Olaparib and Enzalutamide combination treatment were determined to transcriptionally downregulate cell cycle progression signatures. Cell cycle analysis …
-
Inhibition of the endosomal recycling pathway to overcome resistance to cancer therapies
… both inhibitors synergise with tamoxifen and enzalutamide, standard-of-care therapies for breast and prostate cancer. Keywords Cancer, prostate, breast, androgen receptor, estrogen receptor, endosomal recycling pathway, primaquine, monensin, drug resistance, tamoxifen, lapatinib, enzalutamide, …
-
Androgen Receptor and Prostate Cancer Cell Heterogeneity
… cells are resistant to the current AR antagonist enzalutamide. Thus, our study links AR heterogeneity to distinct castration and enzalutamide responses and suggests the urgency in developing novel therapeutics to target AR<sup>-/lo</sup> PCa cells/clones.</p>
-
CaV1.3 Ion channel expression and hormone therapy in prostate cancer
… and/or androgen receptor (AR) antagonists, e.g. Enzalutamide (ENZ). Castrate-resistant disease, where tumours become resistant to hormone therapy, is characterised by limited effective treatments and poor survival outcomes. The aberrant expression and function of ion channels in the oncology …
-
Development of novel lysine targeting covalent inhibitors for Bruton’s tyrosine kinase and casein kinase 2 and synthesis of novel hybrid androgen receptor inhibitors
… compounds designed through covalently linking enzalutamide and EPI-001 through triazole-PEG linkers is reported. The compounds are accessed in 6 synthetic steps performed in parallel for the 5 final target compounds. The compounds display a 50-fold improvement in the cell killing potency …
-
Integration of class 1 HDAC inhibitors into current treatments for prostate cancer
… Androgen signalling inhibitors (ASI), including Enzalutamide (ENZ) and Abiraterone (ABI), are effective treatments for metastatic CRPC however, resistance develops within 24-months of initial exposure in the majority of patients. <br/><br/>Epigenetic silencing of cancer-related genes has been …
-
Engineering Lipid Nanoparticles for sIRNA Delivery to Silence Identified Targest in Cancer Cells
… 3 investigates mechanisms of resistance to enzalutamide in castration-resistant prostate cancer (CRPC). By using gradual and shock resistance induction models, specific molecular targets associated with resistance are identified. These targets provide opportunities for RNAibased therapeutic …
-
Design and Synthesis of Complex and Fluorescent Labeled Cellulose-Based Derivatives for Orally Administered Drug Delivery Systems
… fast crystallizing prostate cancer drug, enzalutamide. I obtained ketone-functionalized cellulose derivatives using oxidation chemistry to produce fluorescent poly- and oligosaccharides (hydroxypropyl cellulose, hydroxypropyl methylcellulose, and hydroxypropyl beta cyclodextrin). …
-
Decoding the RNA cargo of plasma-derived extracellular vesicles in metastatic castration-resistant prostate cancer
… prostate cancer (mCRPC) patients, treated with Enzalutamide in a chemo-naïve setting. Specifically, it incorporates EV physical characterization, EV-RNA and matched cfDNA genomics. The use of total RNA sequencing (RNA-seq) enabled the detection of both coding and non-coding RNAs, regardless …
-
Mixed Polysaccharide Esters for Amorphous Solid Dispersion Oral Drug Delivery Vehicles
… derivatives with poorly water-soluble enzalutamide, posaconazole and celecoxib model drugs, to evaluate their crystallization inhibition properties and the influence of polymer morphology upon structure-property relationships. We expect that these synthetic polymer strategies will offer …
-
Techniques for comparing efficacy and cost-effectiveness of cancer therapies, and improved inference tools
… pathway inhibitors, abiraterone acetate and enzalutamide, have recently become available. They have been developed with the aim of prolonging survival, minimizing complications, and maintaining or improving quality of life in patients with advanced or metastatic CRPC. However, these two …
-
PHYTOCHEMICAL AND SYNTHETIC INVESTIGATIONAL COMPOUNDS AS MODULATORS OF CYTOMETABOLIC AND CYTOSKELETAL DYNAMICS FOR PRE-CLINICAL TARGETING OF PROSTATE CANCER
… the cancer killing effects of docetaxel, enzalutamide, and abiraterone anticancer drugs with synergism in PC cells, by involving multiple cell death pathways. With further studies, the roles and crosstalk of signaling pathways involving lignan’s and other investigational drugs (nelfinavir, …